Second dose of experimental drug may help heart amyloidosis patients

NCT ID NCT07213583

Ongoing Disease control Sponsor: Neurimmune AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a second round of treatment with ALXN2220 is safe and can improve heart function in people with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. About 35 adults who previously received the drug will get it again and be monitored for 48 weeks. The goal is to see if the drug reduces protein buildup and helps the heart work better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID TRANSTHYRETIN CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID TRANSTHYRETIN CARDIOMYOPATHY

Contacts and locations

Show contact details

Locations

CHU Toulouse - Hôpital Rangueil

Toulouse, 31059, France
CHU de Rennes - Hôpital Pontchaillou

Rennes, 35033, France
Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, 28222, Spain
Hôpital Henri Mondor

Créteil, 94000, France
University Medical Center Groningen

Groningen, 9713, Netherlands
Universitätsklinikum Heidelberg

Heidelberg, 69120, Germany